Paper Details

  1. Home
  2. Paper Details

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

Author: , AghaMounzer E, AlsinaMelissa, AndersonKenneth C, AndersonLarry D, AndreescuAstrid C, AttalMichel, Avet-LoiseauHervé, CampagnaroErica L, CohenAdam D, CornellR Frank, FoleyAmy, FulcinitiMariateresa, GasparettoCristina, GentileTeresa, GhobrialIrene M, GiraltSergio A, GodbyKelly N, GowinKrisstina, HashmiHamza, HassounHani, HebertKyle, HurdDavid D, JacobusSusanna J, JagannathSundar, KambleRammurti T, KaufmanJonathan L, KhanAbdullah M, LaubachJacob P, LibbyEdward N, LiedtkeMichaela, LonialSagar, MaglioMichelle E, MasoneKelly, McCarthyPhilip L, MedvedovaEva, MilnerCarter P, MoreauPhilippe, MunshiNikhil C, NadeemOmar, NathwaniNitya, OpenshawThomas H, OrlowskiRobert Z, Paba-PradaClaudia, PasquiniMarcelo C, PerrotAurore, RajeNoopur S, RichardsonPaul G, SamurMehmet K, SchlossmanRobert L, ScottEmma, TorkaPallawi, VoorheesPeter M, WellerEdie A, YeeAndrew J, ZeytoonjianAndrea A, ZonderJeffrey A

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]) was associated with longer progression-free survival (PFS) than RVD alone in patients with newly diagnosed multiple myeloma. The median PFS was 67.5 months in the transplantation group and 46.2 months in the RVD-alone group. No overall survival benefit was observed.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until disease progression, is unknown. METHODS: In thi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35660812

データ提供：米国国立医学図書館（NLM）

Triple Therapy and Transplantation for Myeloma: A Powerful Combination

Multiple myeloma, a type of blood cancer, presents a significant challenge for patients and clinicians. This research explores the effectiveness of a combination therapy that includes triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), autologous stem-cell transplantation (ASCT), and lenalidomide maintenance therapy for newly diagnosed myeloma. The study aimed to determine the impact of this combination on progression-free survival, a measure of how long patients live without their cancer worsening. Think of the body as a complex desert ecosystem, where myeloma disrupts the balance, leading to uncontrolled cell growth. This study explores the effectiveness of a multi-pronged approach to restore balance and combat the disease.

Fighting Myeloma with Multiple Weapons

This phase 3 trial demonstrates that combining triplet therapy (RVD) with ASCT followed by lenalidomide maintenance significantly improves progression-free survival compared to RVD alone. The study found that patients in the combination therapy group experienced a median progression-free survival of 67.5 months compared to 46.2 months in the RVD-alone group. This significant improvement highlights the synergistic effect of combining these different treatment approaches. It is like employing a multi-pronged strategy to combat a desert sandstorm, where each tool plays a vital role in minimizing damage and restoring stability.

A Brighter Future for Myeloma Patients

This research offers a beacon of hope for patients with myeloma, demonstrating the effectiveness of a combination therapy that significantly improves progression-free survival. The study highlights the importance of considering multi-modal treatment approaches to maximize the benefits and minimize the risks of cancer treatment. It is like navigating a treacherous desert, where a well-planned strategy and the right tools can lead to a successful journey.

Dr.Camel's Conclusion

This phase 3 trial provides compelling evidence that combining triplet therapy (RVD) with ASCT and lenalidomide maintenance significantly improves progression-free survival for patients with newly diagnosed multiple myeloma. It underscores the potential of multi-modal treatment approaches in combating this complex disease and offers a brighter outlook for patients navigating this challenging journey.

Date :
  1. Date Completed 2022-07-15
  2. Date Revised 2023-11-14
Further Info :

Pubmed ID

35660812

DOI: Digital Object Identifier

NIHMS1833467

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.